Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer
Li G, Hu J, Cho C, Cui J, Li A, Ren P, Zhou J, Wei W, Zhang T, Liu X, Liu W. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer. Cellular Signalling 2023, 109: 110729. PMID: 37257766, DOI: 10.1016/j.cellsig.2023.110729.Peer-Reviewed Original ResearchConceptsT cell tumor infiltrationTriple-negative breast cancerCD8+ T cell tumor infiltrationBreast cancerTumor infiltrationLack of target receptorsAnti-PD-1 antibodyAggressive subtype of breast cancerModels of triple-negative breast cancerSubtypes of breast cancerPD-L1 expressionEstrogen-positive breast cancerMTOR inhibitor everolimusPositive breast cancerProgression of triple-negative breast cancerReduced tumor growthAvailable treatment optionsCombination treatment strategiesPromote cancer cell survivalTreatment of estrogen-positive breast cancerAttenuate tumor progressionNonspecific cytotoxic agentsCancer cell survivalVascular endothelial cellsPotential therapeutic strategy